Analysts forecast that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will announce ($0.21) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Pieris Pharmaceuticals’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.24). The firm is scheduled to announce its next earnings report on Thursday, August 8th.
On average, analysts expect that Pieris Pharmaceuticals will report full year earnings of ($0.85) per share for the current year, with EPS estimates ranging from ($0.98) to ($0.78). For the next year, analysts forecast that the business will post earnings of ($1.01) per share, with EPS estimates ranging from ($1.37) to ($0.58). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Pieris Pharmaceuticals.
Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its earnings results on Friday, May 10th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.02). Pieris Pharmaceuticals had a negative net margin of 84.75% and a negative return on equity of 64.64%. The firm had revenue of $8.55 million during the quarter, compared to analyst estimates of $7.85 million.
Shares of PIRS opened at $4.70 on Thursday. The stock’s 50-day moving average is $4.13. Pieris Pharmaceuticals has a 12 month low of $2.39 and a 12 month high of $6.55.
A number of institutional investors have recently made changes to their positions in PIRS. SG Americas Securities LLC bought a new stake in Pieris Pharmaceuticals in the fourth quarter valued at about $36,000. BNP Paribas Arbitrage SA bought a new stake in Pieris Pharmaceuticals in the first quarter valued at about $36,000. Prudential Financial Inc. bought a new stake in Pieris Pharmaceuticals in the fourth quarter valued at about $43,000. Alambic Investment Management L.P. bought a new stake in Pieris Pharmaceuticals in the fourth quarter valued at about $59,000. Finally, D. E. Shaw & Co. Inc. increased its holdings in Pieris Pharmaceuticals by 107.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 49,904 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 25,794 shares during the last quarter. 59.70% of the stock is owned by hedge funds and other institutional investors.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Recommended Story: How to trade on quiet period expirations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.